ArticleApplied biochemistry and biotechnology2025
Unraveling the Molecular Mechanisms of cSLE Through Integrated Serum Metabolomics, Network Pharmacology, and Molecular Docking Approaches.
Article in Applied biochemistry and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood-onset systemic lupus erythematosus (cSLE) is recognized as a chronic, systemic autoimmune disorder that manifests during childhood. Compared to adult-onset SLE, cSLE is characterized by higher disease activity and greater cumulative organ damage, thereby requiring more intensive immunosuppressive therapy. Although early diagnosis remains challenging, it is considered essential for improving clinical outcomes. In the present study, the serum metabolomic profiles of 100 cSLE patients and 40 healthy controls were comprehensively analyzed. Through the integration of differentially expressed metabolites, nine key metabolites were identified that effectively distinguished cSLE patients from healthy individuals. Moreover, unsaturated fatty acids were found to potentially modulate the JAK2/STAT3 signaling pathway, suggesting a role in disease progression. Overall, these findings underscore the potential value of investigating unsaturated fatty acids to gain mechanistic insight into cSLE pathogenesis and to uncover novel therapeutic targets.
Indexed as
Identifiers
40884723What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.